Skip to content

Evaluation of Prognostic Monitoring for Women Who Have Completed Standard Treatment for Breast Cancer

Evaluation of Prognostic Monitoring for Women Who Have Completed Standard Treatment for Breast Cancer Via Analysis of Immunoinflammation-related Protein Complexes in Blood

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04145960
Enrollment
200
Registered
2019-10-31
Start date
2019-04-25
Completion date
2025-03-31
Last updated
2019-11-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Brief summary

The relationship between immune inflammation-related protein complexes in blood and recurrence or metastasis of breast cancer will be studied.

Detailed description

200 patients with breast cancer will be followed up. Peripheral venous blood was collected every 3 to 6 months. Change regularity of breast cancer-specific immune inflammation-related protein complexes in blood at different follow-up time points will be studied. The relationship between disease-specific protein complexes and pathological state of patients will be analyzed.

Interventions

None listed

Sponsors

Peking Union Medical College Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
No minimum to 60 Years
Healthy volunteers
No

Inclusion criteria

* Female * Postoperative pathology confirmed invasive breast cancer after surgery for breast tumors * Breast cancer-related chemotherapy and radiotherapy completed * axillary lymph node metastasis ≥ 4 * age ≤ 60 years old

Exclusion criteria

* Male * Aged above 60 * Breast Carcinoma in situ * Women in pregnancy or breastfeeding * Suffering from other malignant tumors * Non-compliant patient

Design outcomes

Primary

MeasureTime frameDescription
immune inflammation-related protein complexes2 yearsThe change of immune inflammation-related protein complexes which is measured by gel permeation chromatography.
blood markers2 yearsThe expression of CA153, CEA, CA125 in the blood of the patients, which are measured by electro-chemiluminescence immunoassay.

Countries

China

Contacts

Primary ContactYali Xu
49950757@qq.com+86-13717761030

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026